Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study

oleh: Yuliya Lytvyn, PhD, Asfandyar Mufti, MD, Hiba Zaaroura, MD, Muskaan Sachdeva, BHSc, Justin D. Lu, MSc, Brian D. Rankin, PhD, Vimal H. Prajapati, MD, Ronald Vender, MD, Jensen Yeung, MD, FRCPC

Format: Article
Diterbitkan: Elsevier 2022-03-01

Deskripsi

Subjek

biologic; efficacy; IL-23; inhibitor; psoriasis; risankizumab